Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions
暂无分享,去创建一个
[1] L B Sheiner,et al. Forecasting individual pharmacokinetics , 1979, Clinical pharmacology and therapeutics.
[2] L B Sheiner,et al. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.
[3] L Aarons,et al. Population pharmacokinetics of tobramycin. , 1989, British journal of clinical pharmacology.
[4] Marie Davidian,et al. Nonlinear Models for Repeated Measurement Data , 1995 .
[5] M O Karlsson,et al. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. , 1997, British journal of clinical pharmacology.
[6] M O Karlsson,et al. Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone , 1998, Clinical pharmacology and therapeutics.
[7] E N Jonsson,et al. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.
[8] G. Molenberghs,et al. Linear Mixed Models for Longitudinal Data , 2001 .
[9] M O Karlsson,et al. Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure. , 2001, British journal of clinical pharmacology.
[10] Mats O Karlsson,et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Mats O Karlsson,et al. Population pharmacokinetics of levosimendan in patients with congestive heart failure. , 2003, British journal of clinical pharmacology.
[12] Staffan Eriksson,et al. Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. , 2003, Haematologica.
[13] Mats O. Karlsson,et al. Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial , 2003, European Journal of Clinical Pharmacology.
[14] Mats O Karlsson,et al. Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS. , 2004, British journal of clinical pharmacology.
[15] Mats O. Karlsson,et al. Assumption Testing in Population Pharmacokinetic Models: Illustrated with an Analysis of Moxonidine Data from Congestive Heart Failure Patients , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[16] Mats O. Karlsson,et al. Automated Covariate Model Building Within NONMEM , 1998, Pharmaceutical Research.
[17] Ene I. Ette,et al. Population Pharmacokinetic Modeling: The Importance of Informative Graphics , 1995, Pharmaceutical Research.
[18] Lewis B. Sheiner,et al. Simultaneous vs. Sequential Analysis for Population PK/PD Data I: Best-Case Performance , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[19] Mats O Karlsson,et al. Pharmacokinetics of Ximelagatran and Relationship to Clinical Response in Acute Deep Vein Thrombosis , 2005, Clinical pharmacology and therapeutics.
[20] Mats O Karlsson,et al. Application of population pharmacokinetics to cladribine , 2005, BMC pharmacology.
[21] Lewis B. Sheiner,et al. Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[22] M. O. Karlsson,et al. The importance of modeling interoccasion variability in population pharmacokinetic analyses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[23] Alain Durand,et al. Evaluation of Bayesian estimation in comparison to NONMEM for population pharmacokinetic data analysis: Application to pefloxacin in intensive care unit patients , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[24] Manuel Hidalgo,et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. , 2006, Journal of the National Cancer Institute.
[25] Grant Langdon,et al. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients , 2006, European Journal of Clinical Pharmacology.
[26] R. Savic,et al. Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults , 2006, Journal of clinical pharmacology.
[27] Andrew C. Hooker,et al. Conditional Weighted Residuals (CWRES): A Model Diagnostic for the FOCE Method , 2007, Pharmaceutical Research.
[28] M O Karlsson,et al. Diagnosing Model Diagnostics , 2007, Clinical pharmacology and therapeutics.
[29] Yaning Wang. Derivation of various NONMEM estimation methods , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[30] Ene I. Ette,et al. Pharmacometrics : the science of quantitative pharmacology , 2007 .
[31] Mats O. Karlsson,et al. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies , 2007, Journal of Pharmacokinetics and Pharmacodynamics.
[32] Comprar Pharmacometrics: The Science of Quantitative Pharmacology | Paul J. Williams | 9780471677833 | Wiley , 2007 .
[33] Yaning Wang,et al. Impact of pharmacometrics on drug approval and labeling decisions: A survey of 42 new drug applications , 2005, The AAPS Journal.
[34] Janet R. Wade,et al. A guide for reporting the results of population pharmacokinetic analyses: A Swedish perspective , 2005, The AAPS Journal.
[35] Mats O Karlsson,et al. Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion. , 2008, British journal of clinical pharmacology.
[36] E. Björk,et al. Models for Plasma Glucose, HbA1c, and Hemoglobin Interrelationships in Patients with Type 2 Diabetes Following Tesaglitazar Treatment , 2008, Clinical pharmacology and therapeutics.
[37] Mats O. Karlsson,et al. Population Pharmacokinetic Analysis of Voriconazole Plasma Concentration Data from Pediatric Studies , 2008, Antimicrobial Agents and Chemotherapy.
[38] Mats O Karlsson,et al. Evaluation of the nonparametric estimation method in NONMEM VI. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.